

L6 ANSWER 6 OF 7 **CAPLUS** COPYRIGHT 2006 ACS on STN  
AN 2005:227234 **CAPLUS**  
DN 142:303612  
TI Sesquiterpenoid compound injections  
IN **Li**, Deshan; Chen, Zeping  
PA Dalian Yida Anpeng Biological and Medical Technology Co., Ltd., Peop. Rep.  
China  
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 34 pp.  
CODEN: CNXXEV  
DT Patent  
LA Chinese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	<b>CN 1454615</b>	A	<u>20031112</u>	CN 2002-117086	20020429
PRAI	CN 2002-117086		20020429		

**AB** The injection (liposome type, nanoliposome type, long circulating liposome type, long circulating nanoliposome type, nano microemulsion type, venous emulsion type, liposome nanosphere type, fat emulsion type, or precursor liposome type) is composed of 0.5-1.5 part  $\geq 70\%$  sesquiterpenoid compound containing plant extract, 3.5-6.0 part surfactant, water-containing medium,  
animal/plant oil or glycerol, or/and C14-22 aliphatic amine. The plant extract is isolated from Aglaia odorata flower, **Toona sinensis** seed, Piper kadsura, Syzygium aromaticum, Commiphora myrrha, etc. The injection may be used for inhibiting and/or treating **neoplasm**, inhibiting **tumor metastasis**, relieving **tumor** pain, and preventing and treating ischemic stroke.

L